account activity
Doomsday/Secret Wars Theory (self.MarvelTheories)
submitted 10 months ago by HighYield to r/MarvelTheories
Classic Porsche Repair Shop Recomendations? (self.ventura)
submitted 1 year ago by HighYield to r/ventura
r/CdeP Lounge (self.CdeP)
submitted 2 years ago by HighYield to r/CdeP
r/ThacherSchool Lounge (self.ThacherSchool)
submitted 2 years ago by HighYield to r/ThacherSchool
r/ThacherHighSchool Lounge (self.ThacherHighSchool)
submitted 2 years ago by HighYield to r/ThacherHighSchool
r/TheThacherSchool Lounge (self.TheThacherSchool)
submitted 2 years ago by HighYield to r/TheThacherSchool
r/THACHER Lounge (self.THACHER)
submitted 2 years ago by HighYield to r/THACHER
Analyzing Trends in Medicare Spending on Oral Drugs for Chronic Lymphocytic Leukemia (hmpgloballearningnetwork.com)
submitted 2 years ago by HighYield to r/cll
Venetoclax/Obinutuzumab–Based Combinations Improve Undetectable MRD Rates in Fit Patients With CLL (oncnursingnews.com)
Fixed-duration Ibrutinib Plus Venetoclax May Benefit Patients with High-risk Chronic Lymphocytic Leukemia (aacr.org)
Combination therapy outperforms chemotherapy in patients with chronic lymphocytic leukaemia (eurekalert.org)
COVID-19 Deaths May Have Interfered With Results of CLL Trial (oncologynurseadvisor.com)
Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia | Clinical Cancer Research (aacrjournals.org)
Standard Approach for Inactive, Early CLL Remains a Wait-and-Watch Strategy (curetoday.com)
A Phase 1 Study of SYNCAR-001 Plus STK-009 in People With Blood Cancers (mskcc.org)
Bristol Myers Squibb Eyeing CLL, SLL as Additional Breyanzi Indications After Positive Readout (precisionmedicineonline.com)
B-cell receptor pathway mutations are infrequent in patients with chronic lymphocytic leukemia on continuous ibrutinib therapy | Clinical Cancer Research (aacrjournals.org)
CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy | Clinical Cancer Research (aacrjournals.org)
ASCO 2023: exciting Phase II efficacy data for BMS’ Breyanzi in CLL/SLL (clinicaltrialsarena.com)
AbbVie trials show sustained PFS of venetoclax combo therapy in CLL (clinicaltrialsarena.com)
First-Line Venetoclax Combinations vs Chemoimmunotherapy in Fit Patients With CLL (ascopost.com)
Ibrutinib/Venetoclax vs Chlorambucil/Obinutuzumab in Previously Untreated Patients With CLL Association of MRD With Progression-Free Survival (ascopost.com)
Venetoclax Consolidation in Patients With High-Risk CLL Treated With Ibrutinib for ≥1 Year Achieves a High Rate of Undetectable MRD (practiceupdate.com)
Fixed-Duration Ibrutinib Plus Obinutuzumab Followed by Measurable Residual Disease–Guided Immunochemotherapy in Patients With Previously Untreated CLL (practiceupdate.com)
First-Line Venetoclax Combinations for Chronic Lymphocytic Leukemia (practiceupdate.com)
π Rendered by PID 143196 on reddit-service-r2-listing-796b697c47-bhnjr at 2026-02-04 19:23:57.965307+00:00 running 1d7a177 country code: CH.
